Condition

Immune Thrombocytopenia (ITP) clinical trials and research

• 12Clinical trials
• 29Countries

Newest Immune Thrombocytopenia (ITP) clinical trials

All recruiting trials (12)

• DZD8586 treatment for adults with primary immune thrombocytopenia (ITP)

  This trial will try different doses of the experimental drug DZD8586 to see if it raises platelet counts and is safe in adults with primary ITP who did not respond to at least one standard treatment.

  Recruiting Phase 2 Dizal Pharmaceuticals · Jinan, Shandong · NCT07294365

• Efgartigimod IV for adolescents (12–17) with chronic immune thrombocytopenia

  This trial will try intravenous efgartigimod to see if it safely raises platelet counts in people aged 12 to 17 with chronic ITP.

  Recruiting at 26 sites Phase 2/3 argenx · Bordeaux and 25 other locations · NCT07194850

• CM336 treatment for relapsed or refractory autoimmune cytopenia

  This trial will test whether CM336, a BCMA/CD3 bispecific antibody given by injection, can help adults with relapsed or refractory autoimmune cytopenias such as ITP, AIHA, or Evans syndrome.

  Recruiting at 3 sites Phase 1/2 Keymed Biosciences Co.Ltd · Zhengzhou, Henan and 2 other locations · NCT07175493

• NVG-2089 for safety and effectiveness in adults with immune thrombocytopenia

  This trial will test whether the investigational drug NVG-2089 is safe and can help raise platelet counts in adults with persistent or chronic immune thrombocytopenia (ITP).

  Recruiting at 3 sites Phase 2 Nuvig Therapeutics, Inc. · Washington D.C., District of Columbia and 2 other locations · NCT07095127

• Teriflunomide plus high-dose dexamethasone versus high-dose dexamethasone alone for adults with newly diagnosed ITP

  This trial tests whether adding teriflunomide to high-dose dexamethasone helps adults with newly diagnosed immune thrombocytopenia raise platelet counts and control bleeding better than dexamethasone alone.

  Recruiting at 3 sites Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07065968

• Budoprutug for adults with immune thrombocytopenia (ITP)

  This trial will test whether two IV doses of budoprutug are safe and can help raise platelet counts in adults with ITP who still have platelets under 30,000/µL after prior treatment.

  Recruiting at 18 sites Phase 1/2 Climb Bio, Inc. · Plovdiv and 19 other locations · NCT07043946

• Gene therapy for patients with relapsed immune thrombocytopenia

  This study is testing a one-time gene therapy injection to see if it can help people with relapsed immune thrombocytopenia who haven't had success with other treatments.

  Recruiting Anhui Provincial Hospital · Changsha, Hunan · NCT06973356

• V-IMMUNE® treatment for immune thrombocytopenia

  This trial tests V-IMMUNE®, an intravenous human immunoglobulin, to raise platelet counts in people aged 1 year and older with immune thrombocytopenia and very low platelets.

  Recruiting Phase 3 On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. · Recife, Pernambuco and 1 other locations · NCT06962631

• Evaluating ESG206 for treating primary immune thrombocytopenia

  This study is testing a new treatment called ESG206 to see if it can safely help people with primary immune thrombocytopenia improve their condition.

  Recruiting Phase 1/2 Shanghai Escugen Biotechnology Co., Ltd · Jinan, Shandong · NCT06853444

• Exploring CM336 for treating immune thrombocytopenia

  This study is testing a new treatment called CM336 to see if it can help adults with hard-to-treat immune thrombocytopenia feel better and manage their low platelet counts.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06799611

• Pirtobrutinib for adults with primary immune thrombocytopenia

  This trial tests whether oral pirtobrutinib can help adults with relapsed or treatment‑resistant primary immune thrombocytopenia (ITP) raise platelet counts and reduce bleeding risk.

  Recruiting at 39 sites Phase 1/2 Eli Lilly and Company · Los Angeles, California and 42 other locations · NCT06721013

• Testing RAY121 for various immunological diseases

  This study is testing a new drug called RAY121 to see if it can safely help people with different immune system diseases like antiphospholipid syndrome and dermatomyositis.

  Recruiting at 48 sites Phase 1 Chugai Pharmaceutical · Orange, California and 76 other locations · NCT06371417

Related topics

Quick answers

How many Immune Thrombocytopenia (ITP) clinical trials are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 29 countries. The most sites are in China (7 trials), Spain (4 trials), France (3 trials), Italy (3 trials), Poland (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1/2: 4, Phase 1: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →